213 related articles for article (PubMed ID: 36183504)
1. Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives.
Yang P; Zhu Y; Zheng Q; Meng S; Wu Y; Shuai W; Sun Q; Wang G
Eur J Med Chem; 2022 Dec; 243():114789. PubMed ID: 36183504
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
3. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
4. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Wnt/β-catenin signaling pathway in human cancers.
Yao H; Ashihara E; Maekawa T
Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
[TBL] [Abstract][Full Text] [Related]
6. Emerging Direct Targeting β-Catenin Agents.
Nalli M; Masci D; Urbani A; La Regina G; Silvestri R
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431838
[TBL] [Abstract][Full Text] [Related]
7. Wnt/β-catenin Signaling Inhibitors.
Zhang X; Dong N; Hu X
Curr Top Med Chem; 2023; 23(10):880-896. PubMed ID: 36872364
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeting the WNT/β-catenin signaling pathway in cancer.
Chatterjee A; Paul S; Bisht B; Bhattacharya S; Sivasubramaniam S; Paul MK
Drug Discov Today; 2022 Jan; 27(1):82-101. PubMed ID: 34252612
[TBL] [Abstract][Full Text] [Related]
9. Is β-Catenin a Druggable Target for Cancer Therapy?
Cui C; Zhou X; Zhang W; Qu Y; Ke X
Trends Biochem Sci; 2018 Aug; 43(8):623-634. PubMed ID: 30056837
[TBL] [Abstract][Full Text] [Related]
10. Identification of dinactin, a macrolide antibiotic, as a natural product-based small molecule targeting Wnt/β-catenin signaling pathway in cancer cells.
Hussain A; Dar MS; Bano N; Hossain MM; Basit R; Bhat AQ; Aga MA; Ali S; Hassan QP; Dar MJ
Cancer Chemother Pharmacol; 2019 Sep; 84(3):551-559. PubMed ID: 31129716
[TBL] [Abstract][Full Text] [Related]
11. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives.
Wang Z; Li Z; Ji H
Med Res Rev; 2021 Jul; 41(4):2109-2129. PubMed ID: 33475177
[TBL] [Abstract][Full Text] [Related]
12. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
Mukherjee N; Panda CK
Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.
Li Q; Sun M; Wang M; Feng M; Yang F; Li L; Zhao J; Chang C; Dong H; Xie T; Chen J
Cancer Sci; 2021 May; 112(5):1695-1706. PubMed ID: 33605517
[TBL] [Abstract][Full Text] [Related]
14. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
15. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Liu Z; Wang P; Wold EA; Song Q; Zhao C; Wang C; Zhou J
J Med Chem; 2021 Apr; 64(8):4257-4288. PubMed ID: 33822624
[TBL] [Abstract][Full Text] [Related]
17. The regulation of β-catenin activity and function in cancer: therapeutic opportunities.
Shang S; Hua F; Hu ZW
Oncotarget; 2017 May; 8(20):33972-33989. PubMed ID: 28430641
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
19. Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities.
Huang P; Yan R; Zhang X; Wang L; Ke X; Qu Y
Pharmacol Ther; 2019 Apr; 196():79-90. PubMed ID: 30468742
[TBL] [Abstract][Full Text] [Related]
20. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
